دورية أكاديمية
Advances in the research and application of neurokinin-1 receptor antagonists.
| العنوان: | Advances in the research and application of neurokinin-1 receptor antagonists. |
|---|---|
| عنوان ترانسليتريتد: | 神经激肽1受体拮抗剂的研究与应用进展. |
| المؤلفون: | Hong X; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China., Ma J; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China., Zheng S; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China., Zhao G; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China., Fu C; College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China. fucy03@zstu.edu.cn. |
| المصدر: | Journal of Zhejiang University. Science. B [J Zhejiang Univ Sci B] 2024 Feb 15; Vol. 25 (2), pp. 91-105. |
| نوع المنشور: | Review; Journal Article |
| اللغة: | English; Chinese |
| بيانات الدورية: | Publisher: Zhejiang University Press Country of Publication: China NLM ID: 101236535 Publication Model: Print Cited Medium: Internet ISSN: 1862-1783 (Electronic) Linking ISSN: 16731581 NLM ISO Abbreviation: J Zhejiang Univ Sci B Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hangzhou, China : Zhejiang University Press, 2005- |
| مواضيع طبية MeSH: | Neurokinin-1 Receptor Antagonists*/pharmacology , Neurokinin-1 Receptor Antagonists*/therapeutic use , Neoplasms*/drug therapy, Humans ; Quality of Life ; Substance P ; Receptors, Neurokinin-1 |
| مستخلص: | Recently, the substance P (SP)/neurokinin-1 receptor (NK-1R) system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019 (COVID-19). Besides, studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis. These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy. This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers, as well as the underlying mechanisms. Furthermore, the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized, such as solid dispersion systems, nanonization, and nanoencapsulation. As a radiopharmaceutical therapeutic, the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors. However, combining NK-1R antagonists with other drugs can produce a synergistic effect, thereby enhancing the therapeutic effect, alleviating the symptoms, and improving patients quality of life in several diseases and cancers. |
| References: | Biomed Res Int. 2016;2016:1959270. (PMID: 26981525) Am J Respir Crit Care Med. 2021 Mar 15;203(6):737-745. (PMID: 32966755) Nat Commun. 2019 Jan 3;10(1):17. (PMID: 30604743) Biochem Biophys Res Commun. 2022 Nov 26;631:72-77. (PMID: 36179498) Invest Ophthalmol Vis Sci. 2020 Jul 1;61(8):29. (PMID: 32697304) Neuropharmacology. 1996;35(8):1121-9. (PMID: 9121615) Cancers (Basel). 2021 May 30;13(11):. (PMID: 34070805) J Control Release. 2000 Mar 1;65(1-2):271-84. (PMID: 10699287) ACS Omega. 2022 Oct 24;7(44):39907-39912. (PMID: 36385804) J Anat. 1993 Aug;183 ( Pt 1):131-40. (PMID: 7505778) Environ Toxicol Pharmacol. 2022 Oct;95:103940. (PMID: 35931359) Pharmaceutics. 2022 Mar 10;14(3):. (PMID: 35335981) Clin Genet. 2020 Oct;98(4):322-330. (PMID: 32266968) J Neurol Sci. 2021 Jan 15;420:117276. (PMID: 33360484) Am J Physiol Gastrointest Liver Physiol. 2019 Dec 1;317(6):G802-G810. (PMID: 31545921) Pharmaceutics. 2018 Jun 23;10(3):. (PMID: 29937483) Mol Biol Rep. 2020 May;47(5):3469-3474. (PMID: 32277443) Mini Rev Med Chem. 2020;20(5):408-417. (PMID: 31721701) Lab Invest. 2010 Aug;90(8):1259-69. (PMID: 20458280) J Cell Biochem. 2018 Feb;119(2):2333-2344. (PMID: 28885729) J Nucl Med. 2014 Oct;55(10):1650-7. (PMID: 25189338) J Infect Dis. 2018 Sep 8;218(8):1324-1335. (PMID: 29788447) Int J Cardiol. 2014 Jan 1;170(3):270-7. (PMID: 24286592) Biomed Res Int. 2021 Aug 02;2021:1383878. (PMID: 34395609) Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19635-19645. (PMID: 31488714) Curr Med Chem. 2021;28(24):4877-4892. (PMID: 33441062) Invest New Drugs. 2019 Feb;37(1):17-26. (PMID: 29721755) Biochem Res Int. 2021 Apr 21;2021:6620708. (PMID: 33976938) J Neurol Neuromedicine. 2016;1(2):29-36. (PMID: 27430034) Ann N Y Acad Sci. 2011 Jan;1217:83-95. (PMID: 21091716) Mol Biol Rep. 2020 Jun;47(6):4263-4272. (PMID: 32436041) Gut. 2021 Apr;70(4):784-795. (PMID: 33127832) Nature. 1998 Mar 26;392(6674):394-7. (PMID: 9537323) Pediatrics. 2020 Jun;145(6):. (PMID: 32179660) Nat Mater. 2013 Nov;12(11):991-1003. (PMID: 24150417) Am J Respir Cell Mol Biol. 2015 Nov;53(5):585-600. (PMID: 26121236) Front Immunol. 2020 Jul 10;11:1708. (PMID: 32754163) Gene. 2015 Apr 15;560(2):205-10. (PMID: 25659767) Eur J Histochem. 2020 Apr 28;64(2):. (PMID: 32363847) Invest New Drugs. 2010 Apr;28(2):187-93. (PMID: 19148578) Drug Des Devel Ther. 2020 Jun 18;14:2413-2422. (PMID: 32606608) Ocul Surf. 2007 Apr;5(2):75-92. (PMID: 17508116) Nat Nanotechnol. 2019 Dec;14(12):1150-1159. (PMID: 31686009) Peptides. 2012 Dec;38(2):318-25. (PMID: 23026680) Cardiovasc Res. 2011 Dec 1;92(3):420-9. (PMID: 21908647) Adv Sci (Weinh). 2021 Nov;8(21):e2101936. (PMID: 34605226) Front Physiol. 2020 Dec 18;11:554766. (PMID: 33391008) J Neuroinflammation. 2022 Aug 3;19(1):198. (PMID: 35922848) Pharmaceutics. 2020 Apr 29;12(5):. (PMID: 32365589) Sci Adv. 2021 Dec 10;7(50):eabk2872. (PMID: 34878828) Eur Heart J. 1993 Nov;14 Suppl I:118-22. (PMID: 7507436) Otolaryngol Head Neck Surg. 2020 Oct;163(4):722-728. (PMID: 32539587) Int J Nanomedicine. 2007;2(1):13-8. (PMID: 17722507) Recent Pat Drug Deliv Formul. 2013 Aug;7(2):111-21. (PMID: 23331062) J Biosci. 2015 Jun;40(2):441-63. (PMID: 25963269) Cell Oncol (Dordr). 2019 Jun;42(3):243-260. (PMID: 30877623) Circulation. 2021 Apr 13;143(15):1513-1525. (PMID: 33550817) Curr Drug Targets. 2006 Aug;7(8):975-92. (PMID: 16918326) J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2371-2379. (PMID: 31442331) Biomed Res Int. 2022 Apr 4;2022:6291504. (PMID: 35434136) J Neurooncol. 2016 Feb;126(3):425-31. (PMID: 26603162) J Allergy Clin Immunol. 2000 Oct;106(4):713-22. (PMID: 11031342) Cancers (Basel). 2020 Sep 20;12(9):. (PMID: 32962202) Int J Oncol. 2014 Oct;45(4):1658-72. (PMID: 25175857) Nat Rev Nephrol. 2022 Oct;18(10):643-662. (PMID: 35974169) Mol Pharm. 2017 Dec 4;14(12):4233-4242. (PMID: 28737398) Sci Rep. 2019 Jul 29;9(1):11004. (PMID: 31358823) Mol Clin Oncol. 2019 Jul;11(1):50-54. (PMID: 31289677) Biochim Biophys Acta Mol Cell Res. 2022 May;1869(5):119221. (PMID: 35134443) Peptides. 2005 Aug;26(8):1369-82. (PMID: 16042977) Science. 1998 Sep 11;281(5383):1640-5. (PMID: 9733503) Molecules. 2020 Aug 18;25(16):. (PMID: 32824729) China CDC Wkly. 2020 Feb 21;2(8):113-122. (PMID: 34594836) J Nucl Med. 2021 Mar;62(3):313-318. (PMID: 33277401) Cell Death Dis. 2022 Jan 10;13(1):41. (PMID: 35013118) Cell Death Differ. 2020 Jan;27(1):176-191. (PMID: 31127201) AAPS PharmSciTech. 2022 Jul 28;23(6):204. (PMID: 35896835) Sci Adv. 2020 Mar 18;6(12):eaaz1050. (PMID: 32206720) Eur J Pharmacol. 2020 Aug 5;880:173168. (PMID: 32423870) J Extracell Vesicles. 2021 Oct;10(12):e12152. (PMID: 34596354) Am J Physiol. 1995 Sep;269(3 Pt 1):L309-17. (PMID: 7573463) Connect Tissue Res. 2020 Nov;61(6):604-619. (PMID: 31443618) J Psychopharmacol. 2013 May;27(5):424-34. (PMID: 23539641) Sci Transl Med. 2021 Nov 24;13(621):eaav7223. (PMID: 34818056) Ocul Surf. 2017 Oct;15(4):652-659. (PMID: 28576753) Cancers (Basel). 2019 Aug 28;11(9):. (PMID: 31466222) Front Pharmacol. 2022 Jan 11;12:811584. (PMID: 35087409) Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1628-1634. (PMID: 31010320) Mucosal Immunol. 2014 Jan;7(1):38-45. (PMID: 23571503) Ageing Res Rev. 2021 Sep;70:101374. (PMID: 34082077) Drug Des Devel Ther. 2020 May 20;14:1943-1952. (PMID: 32546961) Molecules. 2015 Jun 19;20(6):11345-56. (PMID: 26102068) Drug Dev Ind Pharm. 2013 Nov;39(11):1783-92. (PMID: 23240730) Clin Case Rep. 2021 Sep 18;9(9):e04646. (PMID: 34567551) Home Healthc Now. 2018 Mar/Apr;36(2):74-83. (PMID: 29498987) Cancers (Basel). 2022 Apr 30;14(9):. (PMID: 35565383) Physiol Rev. 2014 Jan;94(1):265-301. (PMID: 24382888) J Cell Biochem. 2020 Jun;121(5-6):3031-3041. (PMID: 32115751) Br J Dermatol. 2018 Apr;178(4):e273-e274. (PMID: 29150837) Indian J Surg Oncol. 2021 Apr;12(Suppl 1):93-102. (PMID: 33994734) Mol Biol Rep. 2022 Feb;49(2):1067-1076. (PMID: 34766230) Chest. 2020 Jun;157(6):1647-1655. (PMID: 31958446) Biomed Pharmacother. 2018 Dec;108:263-270. (PMID: 30223097) Neuropeptides. 2016 Aug;58:41-51. (PMID: 26706184) J Clin Med. 2020 Jun 01;9(6):. (PMID: 32492831) Adv Colloid Interface Sci. 2015 Sep;223:40-54. (PMID: 26043877) J Pharm Sci. 2015 Sep;104(9):2777-88. (PMID: 25712830) J Cell Mol Med. 2019 Dec;23(12):7961-7973. (PMID: 30903649) |
| معلومات مُعتمدة: | LD22H310004 the Zhejiang Provincial Natural Science Foundation of China; 2022C03005 the Pioneer and Leading Goose R&D Program of Zhejiang |
| فهرسة مساهمة: | Keywords: Bioavailability; Nanoencapsulation; Neurokinin-1 receptor (NK-1R) antagonist; Pathophysiological disorder; Synergistic therapy; Tumor target Local Abstract: [Publisher, Chinese] 目前研究已经发现神经肽（SP）/神经激肽1受体（NK-1R）拮抗剂系统参与了包括2019冠状病毒病（COVID-19）症状在内的多种人体生理疾病。肿瘤学领域的最新研究表明：NK-1R的上调和SP/NK-1R系统的激活与多种癌症类型的进展和不良临床预后之间存在复杂的相关性，使用NK-1R拮抗剂来调节SP/NK-1R系统可成为一种潜在的广谱抗肿瘤策略。本文综述了NK-1R拮抗剂在人体生理疾病和癌症治疗中的最新应用和潜力以及相关机制，总结了改善NK-1R拮抗剂生物利用度和药效的策略（如固体分散系统、纳米化、纳米封装等），同时探讨了在放射药物治疗中，阿瑞匹坦作为放射配体受体以靶向过表达NK-1R的肿瘤疗法。此外，本文还总结了NK-1R拮抗剂与其他药物的协同效应，为NK-1R拮抗剂的创新应用提供了参考。. |
| المشرفين على المادة: | 0 (Neurokinin-1 Receptor Antagonists) 33507-63-0 (Substance P) 0 (Receptors, Neurokinin-1) |
| تواريخ الأحداث: | Date Created: 20240202 Date Completed: 20240205 Latest Revision: 20240205 |
| رمز التحديث: | 20240205 |
| مُعرف محوري في PubMed: | PMC10835208 |
| DOI: | 10.1631/jzus.B2300455 |
| PMID: | 38303494 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1862-1783 |
|---|---|
| DOI: | 10.1631/jzus.B2300455 |